Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.24 +0.04 (+0.25%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Bumble (BMBL) Stock Pops as Elliott Builds a Stake in Rival Match
Bumble stock is rising on Tuesday as BMBL investors learn of a $1 billion investment in rival dating services company Match. 
Via InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Up Today?
Sarepta Therapeutics stock is rising higher on Tuesday as SRPT investors react to positive comments from company CEO Douglas Ingram. 
Via InvestorPlace
Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday. 
Via Benzinga
Topics Stocks
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
Last year wasn't great for either stock, but that's no reason to ignore them. 
Via The Motley Fool
The Latest Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
Can this struggling stock turn its fortunes around? 
Via The Motley Fool
Analyst Ratings for Sarepta Therapeutics
Via Benzinga
1 Gene Therapy Stock to Buy and Hold for the Long Haul
The biotech has what it takes to overcome recent obstacles. 
Via The Motley Fool
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech... 
Via Talk Markets
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction... 
Via Benzinga
3 Things About Sarepta Therapeutics Every Smart Investor Knows
Mastering this stock requires appreciating a few scientific nuances. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
Both develop medicines for rare diseases, and each aims to conquer a niche market. 
Via The Motley Fool
1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond
Many investors are bailing out, but that might be a mistake. 
Via The Motley Fool
My Take: 4 Strong Growth Stocks to Buy This Week
These strong stocks are still available at a great price. That may not be the case a whole lot longer. 
Via The Motley Fool
3 Monster Stocks in the Making
These stocks could grow much larger over the next few years. 
Via The Motley Fool
3 Stocks You’ll Regret Not Buying Soon: November 2023
These stocks to buy are the ones to scoop up soon for long-term growth as these companies have stable growth catalysts in the coming years. 
Via InvestorPlace
Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy
Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the  
Via Benzinga
Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said HubSpot, Inc. (NYSE: HUBS) is like a "mini-Salesforce, it’s got incredible growth, and people like growth again. 
Via Benzinga
Topics Artificial Intelligence
Is Sarepta Therapeutics Stock a Bad-News Buy?
Analysts still expect some sizable returns from the stock. 
Via The Motley Fool
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?
Just because a stock is "on sale" doesn't inherently make it worth purchasing. 
Via The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript
SRPT earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
What's Going On With Biotech Contract Service Firm Catalent Stock Today?
Catalent Inc (NYSE: CTLT) shares are trading lower due to its significant exposure to Sarepta Therapeutics Inc (NASDAQ: SRPT) on the back of disappointing data from a pivotal gene therapy trial. 
Via Benzinga
Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss
Sarepta Therapeutics Inc's (NASDAQ: SRPT) EMBARK Phase 3 study of Elevidys in ambulatory boys (those who can walk) with Duchenne muscular dystrophy aged 4-7 years failed to  
Via Benzinga
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for... 
Via Benzinga
Topics Intellectual Property
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback